G protein β3 gene variant, vascular function, and insulin sensitivity in type 2 diabetes

Hypertension

Volumn 41, Issue 1, 2003, Pages 124-129

  Fernández Real, José Manuel ^a   Peñarroja, Georgina ^a   Richart, Cristóbal ^b   Castro, Antoni ^a   Vendrell, Joan ^b   Broch, Montserrat ^b   López Bermejo, Abel ^a   Ricart, Wifredo ^a  

^a HOSPITAL JOSEP TRUETA   (Spain)

^b HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

Author keywords

Diabetes mellitus; Endothelium; G protein; Insulin; Nitric oxide; Polymorphism; Vascular resistance

Indexed keywords

C PEPTIDE; DNA; GLYCERYL TRINITRATE; GUANINE NUCLEOTIDE BINDING PROTEIN; HEMOGLOBIN A1C; INSULIN; NITRIC OXIDE; G PROTEIN BETA3 SUBUNIT; G-PROTEIN BETA3 SUBUNIT; HETEROTRIMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; VASODILATOR AGENT;

ALLELE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DNA POLYMORPHISM; DRUG RESPONSE; FEMALE; GLUCOSE TRANSPORT; HEART RATE; HUMAN; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; VASCULAR DISEASE; VASCULAR RESISTANCE; VASODILATATION; ADULT; AGED; BRACHIAL ARTERY; CLINICAL TRIAL; DRUG EFFECT; ECHOGRAPHY; GENETIC POLYMORPHISM; GENETICS; GLUCOSE BLOOD LEVEL; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; BLOOD GLUCOSE; BRACHIAL ARTERY; DIABETES MELLITUS, TYPE 2; FEMALE; HETEROTRIMERIC GTP-BINDING PROTEINS; HUMANS; INSULIN; MALE; MIDDLE AGED; NITROGLYCERIN; POLYMORPHISM, GENETIC; VASODILATION; VASODILATOR AGENTS;

EID: 0037270351     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000042428.24031.73     Document Type: Article

References (33)

1. Neer EJ, Clapham DE. Roles of G protein subunits in transmembrane signalling. Nature. 1988;333:129-134.
2. Siffert W, Rosskopf D, Siffert G, Busch S, Moritz A, Erbel R, Sharma AM, Ritz E, Wichmann HE, Jakobs KH, Horsthemke B. Association of a human G protein β3 subunit variant with hypertension. Nat Genet. 1998;18:45-48.
3. Hegele RA, Anderson C, Young TK, Connelly PW. G protein β3 subunit gene splice variant and body fat distribution in Nunavut Inuit. Genome Res. 1999;9:972-977.
4. Siffert W, Forster P, Jockel KH, Mvere DA, Brinkmann B, Naber C, Crookes R, Du P Heyns A, Epplen JT, Fridey J, Freedman BI, Muller N, Stolke D, Sharma AM, Al Moutaery K, Grosse-Wilde H, Buerbaum B, Ehrlich T, Ahmad HR, Horsthemke B, Du Toit ED, Tiilikainen A, Ge J, Wang Y, Rosskopf D. Worldwide ethnic distribution of the G protein β3 subunit 825T allele and its association with obesity in Caucasian, Chinese and Black African individuals. J Am Soc Nephrol. 1999;10:1921-1930.
5. Moxham CM, Hod T, Malbon CC. Induction of G alpha i2-specific antisense RNA in vivo inhibits neonatal growth. Science. 1993;260:991-995.
6. Feldman RD, Hegele RA. G protein polymorphisms and maternal/neonatal metabolism: still a weight for the answer. Lancet. 2000;355:1201-1202.
7. Gutersohn A, Naber C, Müller N, Erbel R, Siffert W. G protein β3 subunit 825 TT genotype and postpregnancy weight retention. Lancet. 2000;355:1240-1241.
8. Siffert W, Rosskopf D, Moritz A, Wieland T, Kaldenberg-Stasch S, Kettler N, Hartung K, Beckmann S, Jakobs KH. Enhanced G protein activation in immortalized lymphoblasts from patients with essential hypertension. J Clin Invest. 1995;96:759-766.
9. Canessa M, Falkner B, Hulman S. Red blood cell sodium-proton exchange in hypertensive black individuals with insulin-resistant glucose disposal. Hypertension. 1993;22:204-213.
10. Blackmore PF, Assimacopoulos-Jeannet F, Chan TM, Exton JH. Studies on α-adrenergic activation of hepatic glucose output: insulin inhibition of α-adrenergic and glucagon actions in normal and calcium-depleted hepatocytes. J Biol Chem. 1979;254:2828-2834.
11. Londos C, Honnor RC, Dhillon GS. cAMP-dependent protein kinase and lipolysis in rat adipocytes, III: multiple modes of insulin responses by adenylate cyclase regulators. J Biol Chem. 1985;260:15139-15145.
12. Luttrell LM, Hewlett EL, Romero G, Rogol AD. Pertussis toxin treatment attenuates some effects of insulin in BC3H-1 murine myocytes. J Biol Chem. 1988;263:6134-6141.
13. Muller-Wieland D, White MF, Behnke B, Gebhardt A, Neumann S, Krone W, Kahn CR. Pertussis toxin inhibits autophosphorylation and activation of the insulin receptor kinase. Biochem Biophys Res Commun. 1991;181:1479-1485.
14. iα2. Nature. 1996;379:840-844.
15. i-proteins. J Cell Biochem. 1994;54:309-319.
16. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest. 1994;94:2511-2515.
17. 2-adrenergic vasorelaxation by a pertussis toxin mechanism. Hypertension. 1997;30:1128-1134.
18. Piatti P, Fragasso G, Monti LD, Caumo A, Van Phan C, Valsecchi G, Costa S, Fochesato E, Pozza G, Pontiroli AE, Chierchia S. Endothelial and metabolic characteristics of patients with angina and angiographically normal coronary arteries. Comparison with subjects with insulin resistance syndrome and normal controls. J Am Coll Cardiol. 1999;34:1452-1460.
19. Catalano M, Carzaniga G, Perilli E, Jun T, Scandale G, Andreoni S, Carotta M. Basal nitric oxide production is not reduced in patients with non-insulin-dependent diabetes mellitus. Vasc Med. 1997;2:302-305.
20. Pieper GM. Review of alterations in endothelial nitric oxide production in diabetes: protective role of arginine on endothelial dysfunction. Hypertension. 1998;31:1047-1060.
21. Piatti PM, Monti LD, Zavaroni I, Valsecchi G, Van Phan C, Costa S, Conti M, Sandoli EP, Solerte B, Pozza G, Pontiroli AE, Reaven G. Alterations in nitric oxide/cyclic-GMP pathway in nondiabetic siblings of patients with type 2 diabetes. J Clin Endocrinol Metab. 2000;85:2416-2420.
22. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340:1111-1115.
23. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Berkowitz K, Marroquin A, Goico J, Ochoa C, Azen SP. Response of pancreatic β-cells to improved insulin sensitivity in women at high risk for type 2 diabetes. Diabetes. 2000;49:782-788.
24. s deficiency. J Clin Endocrinol Metab. 1999;84:4127-4131.
25. McVeigh GE, Brennan GM, Johnston GD, McDermott BJ, McGrath LT, Henry WR, Andrews JW, Hayes JR. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1992;35:771-776.
26. Watts GF, O'Brien SF, Silvester W, Millar JA. Impaired endothelium-dependent and independent dilatation of forearm resistance arteries in men with diet-treated non-insulin-dependent diabetes: role of dyslipidemia. Clin Sci. 1996;91:567-573.
27. Adams MR, Robinson J, McCredie R, Seale JP, Sorensen KE, Deanfield JE, Celermajer DS. Smooth muscle dysfunction occurs independently of impaired endothelium-dependent dilation in adults at risk of atherosclerosis. J Am Coll Cardiol. 1998;32:123-127.
28. McVeigh GE, Brennan GM, Hayes R, Johnston GD. Primary nitrate tolerance in diabetes mellitus. Diabetologia. 1994;37:115-117.
29. Anderson TJ, Meredith IT, Ganz P, Selwyn AP, Yeung AC. Nitric oxide and nitrovasodilators: similarities, differences, and potential interactions. J Am Coll Cardiol. 1994;24:555-566.
30. Mehta JL. Endothelium, coronary vasodilation, and organic nitrates. Am Heart J. 1995;129:382-391.
31. Torfgard K, Ahlner J, Axelsson KL. Relaxation of bovine mesenteric arteries by glyceryl trinitrate and other nitro-compounds: evidence for partly different mechanisms of action. Pharmacol Toxicol. 1990;67:216-221.
32. Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin: direct measurement in vascular endothelial cells. J Clin Invest. 1996;98:894-898.
33. Emilien G, Ponchon M, Caldas C, Isacson O, Maloteaux JM. Impact of genomics on drug discovery and clinical medicine. Q J Med. 2000;93:391-423.